Glenmark Pharma bags USFDA nod for generic version of Enstilar Foam

Written by Ruchika Sharma Published On 2022-05-09T11:00:23+05:30 | Updated On 9 May 2022 3:41 PM IST

Glenmark Pharma bags USFDA nod for generic version of Enstilar Foam

Mumbai: Drugmaker, Glenmark Pharmaceuticals Inc., USA, today announced that it has received tentative approval from the United States Food & Drug Administration (USFDA) for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%, the generic version of Enstilar Foam, 0.005%|0.064%, of Leo Pharma AS.

Betamethasone dipropionate is used to treat inflammation of the skin and dermatitis while calcipotriene is used to treat plaque psoriasis of the skin and scalp.

According to IQVIA sales data for the 12 month period ending March 2022, the Enstilar Foam, 0.005%|0.064% market achieved annual sales of approximately $115.2 million*.

Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the U.S. FDA.

In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharmaceuticals Ltd. is a global innovation-driven pharmaceutical company with presence across Specialty, Generics and OTC businesses. Globally, Glenmark focuses on the following key therapy areas: respiratory, dermatology and oncology.

The company has been listed on the Dow Jones Sustainability Index (DJSI), under the category of emerging markets for the fourth consecutive year in a row, most recently in 2021. DJSI is one of the world's most respected and widely accepted sustainability benchmarks globally with only the top ranked companies in terms of Corporate Sustainability within each industry are featured in the index

glenmark newsglenmarkusfdacalcipotrienebetamethasone dipropionate foamenstilar foamleo pharma

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751